Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Rheumatology & Arthritis market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

7 Item(s)

Page 1 of 1

  1. Global Gout Therapeutics Market 2016-2020

    By: Technavio
    , Published: Oct-2016
    , Product code: IRTNTR10483
    The report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.
    $2,500.00

  2. Global Rhematoid Arthritis Drugs Market 2016-2020

    By: Technavio
    , Published: Feb-2016
    , Product code: IRTNTR8751
    The report covers the present scenario and the growth prospects of the global RA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat the disease.
    $3,000.00

  3. Global Psoriatic Arthritis Market 2015-2019

    By: Technavio
    , Published: Dec-2015
    , Product code: IRTNTR7499
    In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.
    $3,000.00

  4. Trends in Therapeutic Partnering

    By: Current Partnering
    , Published: Aug-2014
    , Product code: CP2290-
    Provides a detailed understanding and analysis of the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014
    $3,995.00

  5. Global Rheumatoid Arthritis Drugs Market 2014-2018

    By: Technavio
    , Published: Jul-2014
    , Product code: IRTNTR3808
    About Rheumatoid Arthritis RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA.
    $2,500.00

  6. Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

    By: GBI Research
    , Published: Oct-2013
    , Product code: GBIHC307MR-
    GBI Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.
    $3,500.00

  7. Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion

    By: GBI Research
    , Published: Jan-2013
    , Product code: GBIHC273MR-
    GBI Research, the leading business intelligence provider, has released its latest research, “Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion”. The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selling drugs. The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expiries in the forecast period and yet more monoclonal antibodies in development will change the dynamics in and this highly lucrative market in the forecast period until 2018.
    $3,500.00

7 Item(s)

Page 1 of 1